MorphoSys to Present at Six Investor Conferences

3 mei 2011 MorphoSys AG / MorphoSys to Present at Six Investor Conferences . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that management will present at six investor conferences in May 2011. Deutsche Bank's 36(th) Annual Healthcare Conference Date:               May 2-4, 2011 Venue:             Boston, USA Participants:   Dr. Simon Moroney, CEO of MorphoSys AG                         Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR Société Générale Corporate and Investment Banking: 6(th) Mid & Small Caps Conference Date:             May 5-6, 2011 Venue:          Nice, France Participant:   Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR Deutsche Bank's German & Austrian Corporate Conference 2011 Date:             May 19-20, 2011 Venue:          Frankfurt, Germany Participants: Dr. Simon Moroney, CEO of MorphoSys AG                        Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR BioEquity Europe Date:             May 23-24, 2011 Venue:          Paris, France Participant:   Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR Helvea's European Healthcare Tour 2011 Date:             May 24, 2011 Venue:          Frankfurt, Germany Participant:   Dr. Simon Moroney, CEO of MorphoSys AG UBS Global Specialty Pharmaceuticals Conference 2011 Date:             May 24-25, 2011 Venue:          London, UK Participants: Dr. Simon Moroney, CEO of MorphoSys AG                      Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR The PDF versions and, if available, live and archived webcasts of company presentations are provided at www.morphosys.com About MorphoSys: MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visithttp://www.morphosys.com/ HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are registered trademarks of MorphoSys; arYla(TM) is a trademark of MorphoSys. This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned. For more information, please contact: MorphoSys AG Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR Tel: +49 (0) 89 / 899 27-122 Mario Brkulj Senior Manager Corporate Communications & IR Tel: +49 (0) 89 / 899 27-454 Jessica Kulpi Specialist Corporate Communications & IR Tel: +49 (0) 89 / 899 27-332 investors@morphosys.com --- End of Message --- MorphoSys AG Lena-Christ-Str. 48 Martinsried / München Germany WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP; Listed: Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Bayerische Börse München, Freiverkehr in Niedersächsische Börse zu Hannover, Prime Standard in Frankfurter Wertpapierbörse, Regulierter Markt in Frankfurter Wertpapierbörse; Conference Announcements May 2011: http://hugin.info/130295/R/1511633/447050.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: MorphoSys AG via Thomson Reuters ONE [HUG#1511633]